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Usefulness of Plasmodium falciparum-specific
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clearance and detection of recurrent infections
after artemisinin-based combination therapy
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Anders Björkman1 and Andreas Mårtensson1,3
Abstract
Background: Rapid diagnostic test (RDT) is an important tool for parasite-based malaria diagnosis. High specificity
of RDTs to distinguish an active Plasmodium falciparum infection from residual antigens from a previous infection is
crucial in endemic areas where residents are repeatedly exposed to malaria. The efficiency of two RDTs based on
histidine-rich protein 2 (HRP2) and lactate dehydrogenase (LDH) antigens were studied and compared with two
microscopy techniques (Giemsa and acridine orange-stained blood smears) and real-time polymerase chain reaction
(PCR) for assessment of initial clearance and detection of recurrent P. falciparum infections after artemisinin-based
combination therapy (ACT) in a moderately high endemic area of rural Tanzania.
Methods: In this exploratory study 53 children < five years with uncomplicated P. falciparum malaria infection were
followed up on nine occasions, i.e., day 1, 2, 3, 7, 14, 21, 28, 35 and 42, after initiation of artemether-lumefantrine
treatment. At each visit capillary blood samples was collected for the HRP2 and LDH-based RDTs, Giemsa and
acridine orange-stained blood smears for microscopy and real-time PCR. Assessment of clearance times and
detection of recurrent P. falciparum infections were done for all diagnostic methods.
Results: The median clearance times were 28 (range seven to >42) and seven (two to 14) days for HRP2 and LDH-
based RDTs, two (one to seven) and two (one to 14) days for Giemsa and acridine orange-stained blood smear and
two (one to 28) days for real-time PCR. RDT specificity against Giemsa-stained blood smear microscopy was 21% for
HRP2 on day 14, reaching 87% on day 42, and ≥96% from day 14 to 42 for LDH. There was no significant
correlation between parasite density at enrolment and duration of HRP2 positivity (r = 0.13, p = 0.34). Recurrent
malaria infections occurred in ten (19%) children. The HRP2 and LDH-based RDTs did not detect eight and two of
the recurrent infections, respectively.
Conclusion: The LDH-based RDT was superior to HRP2-based for monitoring of treatment outcome and detection
of recurrent infections after ACT in this moderately high transmission setting. The results may have implications for
the choice of RDT devices in similar transmission settings for improved malaria case management.
Trial registration: Clinicaltrials.gov, NCT01843764
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Background
Parasite-based Plasmodium falciparum diagnosis is gen-
erally recommended by the World Health Organization
(WHO) to target artemisinin-based combination therapy
(ACT) to patients with confirmed malaria infections [1].
This is important in order to prevent overuse of ACT,
reduce costs, minimize development and spread of anti-
malarial drug resistance and to improve management of
other causes of fever [2,3]. The availability of malaria
rapid diagnostic tests (RDTs) constitutes an opportunity
for parasite-based malaria diagnosis in rural African set-
tings beyond the reach of microscopy services [4].
Malaria RDTs are based on detection of parasite anti-
gens. The main antigen targeted is histidine-rich protein
2 (HRP2), which has proven to be a highly sensitive and
stable marker for identification of P. falciparum infec-
tion. However, a concern with HRP2-based RDTs is the
presence of residual antigenaemia resulting in persistent
positive test results during several weeks after a success-
ful treatment [5,6]. This is of particular concern in
moderate/high transmission areas where false positive
RDTs may frequently result in provision of anti-malarial
treatment to patients who are not malaria infected. This
phenomenon may also impair health workers trust in
and adherence to RDT results [7,8].
Another antigen used in RDTs is parasite-specific
lactate dehydrogenase (LDH), either species specific, i.e.,
P. falciparum LDH (PfLDH) and Plasmodium vivax
(PvLDH), or pan-Plasmodium (pLDH), detecting all five
human malaria species [9]. LDH-based RDTs have gen-
erally been shown to be less heat stable and sensitive
than HRP2-based RDTs for detection of P. falciparum,
but they are more specific since LDH is rapidly cleared
from the blood following a successful anti-malarial treat-
ment. Consequently, LDH-based RDTs do not remain
positive after parasite clearance [2,10]. Interestingly,
some recently available PfLDH-based RDTs have shown
sensitivities and heat stabilities similar to HRP2-based
RDTs [11-14].
Previous RDT studies in this particular field have
mainly focused on post-treatment clearance and have
primarily followed patients until the tests have become
negative [12,13]. Thus, insufficient data are available on
the efficiency of RDTs to identify recurrent infections
after recently cleared infections in moderate/high trans-
mission areas. This may be of particular importance in
an era of increasing drug resistant malaria [15]. The aim
of this study was therefore to investigate clearance and
detection of recurrent P. falciparum infections of HRP2
and LDH-based RDTs during 42 days after initiation of
artemether-lumefantrine treatment in children with un-
complicated malaria in a moderately high endemic area
of rural Tanzania. Furthermore, since no previous study
has included clearance by polymerase chain reaction
(PCR) as a comparator, this was done to allow a more
comprehensive evaluation of RDT for monitoring of
anti-malarial treatment outcome. The entire assessment
herein reported thus included two RDTs (HRP2 and
LDH-based) for antigen detection, compared with two
microscopy techniques (Giemsa-stained thick blood
smears and acridine orange-stained thin blood smears)
for whole parasite detection and real-time PCR for de-
tection of parasite DNA.
Methods
Study site and population
This health facility-based study was conducted during
the peak seasons for malaria transmission, in June to
September 2009 and July to October 2010 at Mlandizi
health centre, Kibaha district and during March to
May 2011 in Fukayosi dispensary, Bagamoyo district,
both located in Coast Region, Tanzania. Artemether-
lumefantrine was introduced as first-line treatment for
uncomplicated malaria in 2006 in the study area,
whereas RDT had not yet been implemented for
parasite-based malaria diagnosis. At the time of the
trial malaria transmission was considered to be moder-
ately high in both study sites.
The Mlandizi health centre provides basic in- and out-
patient care for a population of approximately 33,000.
Laboratory services, including malaria microscopy, are
available during office hours. The monthly blood smear
positivity rate among febrile children < five years of age
was 33% (range 20-48%) and 15% (range 11-21%) during
the sampling period in 2009 and 2010, respectively.
There was a period of artemether-lumefantrine stock-out in
Mlandizi in 2009. During this period patient recruitment
was stopped. There was an on-going insecticide-treated
bed net campaign in the area markedly reducing the inci-
dence of malaria among children < five years between 2009
and 2010.
Fukayosi dispensary provides basic outpatient care for
a population of about 7,000. Malaria microscopy service
is available seven days a week. Malaria blood smear posi-
tivity rate was 19% (74/384) among febrile children < five
years of age during the conduct of the trial.
Participating laboratory staff and study nurses at the
two study sites received one day’s training in perform-
ance and interpretation of both RDTs before the start of
the study.
Study design and sample collection
Children between six and 59 months presenting at the
study sites with fever, i.e., measured axillary temperature
of ≥37.5°C or a history of fever during the preceding
24 hours, and a positive screening blood slide for P.
falciparum mono-infection with a parasite density of
2,000-250,000/μL, and willing/able to comply with the
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42 days follow-up were eligible to participate in the
study. Children with a history of anti-malarial drug
intake within two weeks or symptoms/signs of severe
disease were excluded. Written informed consent was
obtained from a parent/guardian of all enrolled children.
At enrolment, i.e., day 0, a complementary finger-prick
capillary blood sample was taken for two thick and thin
smears, and two RDTs. In addition, approximately 50 μL
of blood was spotted on a filter paper. All enrolled
children were treated with artemether-lumefantrine
(Coartem®) in standard doses based on body weight,
according to national treatment guidelines [16]. Only
the initial drug dose was given under supervision. En-
rolled children were requested to return for clinical re-
view and blood sampling on days 1, 2, 3, 7, 14, 21, 28, 35
and 42, or anytime if condition deteriorated or fever re-
occurred. At each follow-up visit all day 0 blood tests
were repeated, except for the Giemsa-stained thin smear,
which was used for confirmation of P. falciparum
mono-infection solely on day 0. A case record form was
completed at enrolment by a clinical officer, with clinical
and demographic information, including age, sex and in-
formation on use of insecticide-treated bed nets. Body
temperature, symptoms and prescription of drugs were
recorded in the case record forms on all visits.
Whenever fever and/or any other symptoms/signs of
disease re-occurred during follow-up, a Giemsa-stained
blood slide was to be read directly at the health centre
and if positive for P. falciparum the child was retreated
with artemether-lumefantrine.
The only incentive given to the study participants was
bus fares to cover travel costs during follow up visits.
Laboratory procedures
Rapid diagnostic tests
Two RDTs, ParaHIT ®f (Span Diagnostics Ltd, Surat,
India), detecting P. falciparum-specific HRP2 antigen
(hereafter referred to as HRP2) and CareStart™ Malaria
(G0151), (Access Bio, Inc, NJ, USA), detecting P. falcip-
arum-specific LDH antigen (hereafter referred to as
LDH), were performed and interpreted on site according
to the manufacturer’s instructions. ParaHit was, at the
time of the study, approved by the Tanzanian National
Malaria Control Programme and was the most deployed
RDT. The single Pf CareStart test was chosen based on
the heat stability and performance of the CareStart pan-
LDH test in the WHO product testing 2009, where it
was among the best performing LDH-based tests for P.
falciparum detection [17]. Both RDTs are two band
tests, i.e., one test band specific for P. falciparum and
one control band.
A laboratory technician or study nurse, blinded to
any Giemsa-stained blood smear result, performed,
interpreted and recorded the RDT results. Very faint
bands at the test line position were to be defined as posi-
tive. Band intensity was not recorded. In case the control
line did not appear, the result was considered invalid
and the test was repeated. The RDT kits were stored
at <30°C prior to use, the temperature being recorded
daily.
Giemsa-stained blood smear microscopy
One of the two thin blood smears collected on day 0
and the thick blood smears from all sampling points
were stained with 5% Giemsa for 20 minutes at the
health facilities, after which they were transported once
weekly to Muhimbili University of Health and Allied
Sciences (MUHAS) in Dar es Salaam. The day 0
Giemsa-stained thin smear was examined for confirm-
ation of P. falciparum mono-infection. One of the two
thick smears was examined by two independent, experi-
enced microscopists, who were unaware of the RDT re-
sults, at MUHAS. A total of 200 microscopic fields
(×100 magnification) were examined before a smear was
considered negative. Asexual parasite densities were cal-
culated by counting parasites against 200 white blood
cells (WBC), assuming 8,000 WBC/μL of blood. If less
than 10 parasites were detected per 200 WBC, estimates
were made against 500 WBC [18]. Gametocytaemia was
assessed by reading 200 microscopic fields. All blood
slides with discrepant results, defined as >50% difference
in parasite density or a positive versus negative result
between the readers, were subjected to a third
blinded reading at Karolinska Institutet (KI), Sweden. In
addition, all blood slides from children showing a nega-
tive thick blood smear and a positive PCR at the same
time point, as well as a random sample of 10% of all
blood slides, plus the blood slides from the time point of
each participant with the last CareStart positive, and the
first CareStart negative results, were subjected to mi-
croscopy reading at KI for quality control. The mean of
the two most concordant counts were used to calculate
the final parasite density [18]. In case of discrepancy re-
garding positive versus negative results between the first
two readers and the third, the third reading at KI was
defined as decisive.
Acridine orange blood slide microscopy
The thin blood smears from all sampling points were
subjected to acridine orange staining and reading at
Muhimbili University Hospital. The thin smears were
fixed in methanol. A solution of 0.01% acridine orange
in phosphate buffer (pH 7.2) with 5% glycerine was then
applied to the smears, which were read in a fluorescence
microscope at ×40 magnification [19]. The results were
recorded as either positive or negative, i.e., parasite
counts were not assessed. The microscopists were un-
aware of all previous RDT and microscopy results.
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DNA detection by PCR
Approximately 50 μL of blood seeded on a filter paper
(Whatman 3MM®) from all sampling points were col-
lected for molecular analysis. The filter papers were
dried and put in individual plastic bags and transported
to KI. The filter papers were stored at <30°C until
processed. Three 3-mm punches (approximately 10–
15 μL) from each filter paper sample were extracted with
a modified version of the ABI 6100 Nucleic Acid Prep
Station protocol (Applied Biosystems, USA) as previ-
ously described [20]. DNA was eluted in 200 μL of
buffer. All samples were analysed for presence of Plas-
modium DNA by an 18S rDNA probe based real-time
PCR assay [21]. A cut-off value for positivity was set at a
cycle threshold (Ct) of <40. All samples were run in
triplicates. Samples where one out of three had a Ct-
value <40 were repeated in triplicates with the same
real-time PCR. Samples with repeated single Ct-values <40
or a Ct average of >38.5 were subjected to a confirmatory/
decisive P. falciparum-specific nested PCR [22]. Two posi-
tive P. falciparum controls (5, 10 or 50 parasites/μL) as well
as negative controls were included in each 96-well PCR
plate.
PCR genotyping to distinguish re-infections from
recrudescence
Filter-paper blood spots from patients with recurrent
PCR positivity during follow-up were re-extracted using
the Chelex-100 method [23]. Stepwise genotyping with
three highly polymorphic genetic markers, i.e., the mero-
zoite surface protein (msp) 1, msp 2 and glutamate rich
protein (glurp) was performed according to standard
protocols to differentiate re-infection (new infection)
from recrudescence (treatment failure). For each marker,
recrudescence was defined as the presence of at least
one matching allelic band and re-infections were de-
fined as the absence of any matching allelic band in
samples at enrolment (day 0) and at day of recurrent
infection [24,25].
Definition of clearance time and recurrent infections
Clearance time was defined as the first sampling day
after initiation of treatment when a test result was nega-
tive. There were two exceptions to this. First, when a
RDT result turned negative for one sampling day,
followed by a positive RDT result again the following
sampling day, the negative result was ignored if the PCR
and/or BS results did not indicate presence of a recur-
rent infection. Second, when one negative PCR result
was followed by a positive PCR result the following sam-
pling day up to day 7, the negative result was ignored.
From day 14 and onwards the clearance time was calcu-
lated from the first day with negative result.
Recurrent infection was defined as detection of P. fal-
ciparum DNA (PCR) confirmed by a positive Giemsa-
stained blood smear microscopy and/or LDH during
follow-up after the initial infection had been cleared.
Study outcomes and statistical analysis
The primary outcomes were clearance time and detec-
tion of recurrent infection with the five diagnostic tests.
Secondary outcomes included specificity of the two
RDTs against Giemsa-stained blood smear microscopy
(gold standard), identification of PCR-adjusted re-infection/
recrudescence among the recurrent infections and correl-
ation between parasite density at enrolment and persistence
of HRP2. In the calculation of correlation between day 0
parasite densities and duration of HRP2 positivity, seven
children were included who had cleared HRP2 positivity
before they were lost to follow-up. These seven children
were not included in any other analysis.
The study was considered exploratory, which pre-
cludes a power calculation. A sample of ≥50 children
was predefined.
Data were entered in Microsoft Excel® and analysed
using STATA 12® software. Categorical variables were
compared using Fisher’s exact test. Pearson linear corre-
lations were calculated in SPSS. Sensitivity and specifi-
city of acridine orange against Giemsa-stained blood
smear microscopy (gold standard) and both microscopic
methods against PCR (gold standard) was calculated.
Statistical significance was stated at the 5% level and
95% confidence intervals (CI) are presented.
Ethical considerations
The study was conducted in accordance with the Declar-
ation of Helsinki and Good Clinical and Laboratory Prac-
tices. It was approved by the Directorate of Research and
Publications, MUHAS (Ref.No.MU//RP/AEC/Vol.XIII/142)
and the Regional Ethics Committee, Stockholm, Sweden.
The study is registered at www.clinicaltrials.gov with
study identifier NCT01843764.
Results
Study subjects
The flow of patients through the trial is outlined in
Figure 1. Two children were excluded from the analysis
due to high parasite densities at enrolment, i.e., 992,000
and 494,400/μL. Another 16 children were not able to
fulfil the stipulated follow-up, the most common reason
being leaving the study area or long distance to the
health centre.
All children were positive with both RDTs at day of
inclusion. Baseline characteristics of the 53 children
included in the analysis are presented in Table 1.
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Clearance time
The calculations for HRP2 clearance are based on the 43
children without recurrent infection during follow-up,
since eight of the ten children with parasite recurrence
remained HRP2-positive from enrolment up to the time
of recurrent infection. All other tests, i.e., LDH, Giemsa
and acridine orange-stained blood smears as well as
PCR cleared before parasite recurrence. Consequently,
clearance calculations for these tests are based on data
from all 53 children. The median clearance times for the
five diagnostic tests are presented in Figure 2 and their
respective positivity rates at each sampling point are
shown in Figure 3.
The geometric mean clearance time for HRP2 was
26.4 (95% CI 23.0-30.3) days. One patient cleared HRP2
by day 7 and three remained positive up to day 42 (last
day of follow-up). The false positivity rates for HRP2
against PCR on days 14, 21, 28, 35 and 42 were 80% (32/
40), 64% (27/42), 43% (18/42), 24% (10/42) and 7% (3/
41), respectively. All PCR positive results were also
Figure 1 Flow of patients through the study.
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HRP2-positive throughout the study. There was no sig-
nificant correlation between parasite density at enrol-
ment and duration of HRP2 positivity (r = 0.13, p = 0.38)
(Figure 4). For LDH the mean clearance time was
5.5 days (95% CI 4.5-6.7). No significant correlation
between parasite density at enrolment and duration of
LDH positivity was observed (r = 0.21, p = 0.11).
The mean clearance time for Giemsa-stained blood
smears was 2.0 days (95% CI 1.8-2.3). Four children (8%)
remained positive by microscopy until day 3. Two children
were microscopy positive day 2 and 3, respectively, with
parasite densities of 16 and 32/μL each. However, PCR was
negative for both samples at these time points. There was
no significant association between clearance times of
Giemsa-stained blood smears and HRP2 (p = 0.50).
Acridine orange-stained blood smears had a mean
clearance time of 2.1 days (95% CI 1.9-2.3). The mean
clearance time for PCR was 2.9 days (95% CI 2.3-3.6).
Persistent PCR positivity up to day 7, 14 and 21 was ob-
served in one, one and two children, respectively. In two
of these four children, solely gametocytes were detected
by Giemsa-stained blood smear microscopy at two and
three sampling points, respectively, during the time of
persistent PCR positivity.
Recurrent infections
Ten children had recurrent P. falciparum infection
during the 42 day follow-up as assessed by PCR,
Giemsa-stained blood smear and/or LDH. One recurrent
infection was defined as recrudescence, six as re-
infections, whereas three were undetermined by PCR
genotyping (Table 2). Eight of these ten children had
remaining HRP2 positivity from the initial infection.
Thus, only two recurrent infections, both occurred on
day 35, were detected by HRP2. Conversely, LDH
detected eight (80%) recurrent infections at the day of
parasite recurrence. Furthermore, one additional child
had a positive LDH result on the following visit.
Giemsa-stained blood smear microscopy identified eight
of the ten recurrent infections, whereas acridine orange
detected one. PCR identified all ten infections at the
time of parasite recurrence. However, six more patients
experienced a single occasion of PCR positivity during
follow-up between days 21 and 42. All these six children
were asymptomatic by the time of the transient PCR
positivity. Except for two patients who were still HRP2-
positive, all other tests were negative at the time of PCR
positivity. Thus, none of the six children fulfilled the def-
inition of recurrent infection. Cumulative positivity by
Table 1 Baseline characteristics of the 53 children
included in the analysis
Age in months, mean 42 (range 10–59)
Sex male/female 35/18
Axillary temperature °C, mean 37.7 (range 37.0-39.0)
Axillary temperature ≥37.5°C 83% (44/53)
Duration of fever, mean days 2.5 (range 1–4)
Other complaints* 64% (34/53)
Geometric mean parasite density /μL 37,640 (range 2,000-250,000)
Sleeping under insecticide-treated
bed net
85% (45/53)
*vomiting n = 18.
abdominal pain n = 9.
cough n = 11.
diarrhoea n = 3.
Figure 2 Median clearance times for the five diagnostic tests. N = number of patients included in the analysis. BS = Giemsa-stained blood
smear. AO = acridine orange-stained blood smear. * Last day of follow-up = day 42.
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the respective diagnostic tests for the ten recurrent in-
fections detected during follow-up is shown in Figure 5.
Five children had fever at the time of detection of recur-
rent infection (Table 2). Four of them had their Giemsa-
stained blood smear read on site and were immediately di-
agnosed and retreated with artemether-lumefantrine. The
fifth child did not have the blood smear read on site due to
symptoms of respiratory tract infection. This child received
antibiotics and improved clinically.
Sensitivity and specificity
The specificities of HRP2 and LDH against Giemsa-
stained blood smear microscopy between days 3 and 42
are shown in Table 3. Compared with PCR the overall
(days 0–42) sensitivities and specificities were 68% (95%
CI 61–75) and 99% (CI % 98–100) for Giemsa, and 61%
(95% CI 53–68) and 98% (95% CI 96–99) for acridine
orange-stained blood smear microscopy, respectively.
The sensitivity and specificity of acridine orange against
Figure 3 Positivity rates at each sampling point by the five diagnostic tests. HRP2 data represent 43 patients and the remaining diagnostic
tests 53 patients. HRP = HRP2 based RDT. LDH = LDH based RDT. BS = Giemsa-stained blood smear. AO = acridine orange-stained blood smear.
PCR = real-time PCR.
Figure 4 Correlation between parasite density at enrolment and duration of HRP2 positivity. N = 52, including 43 children without re-
infection, two with cleared positivity before re-infection and seven with cleared positivity before being lost to follow-up. Correlation coefficient
(r) = 0.13 (p = 0.38).
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Giemsa-stained blood smear microscopy were 81%
(95 CI 73–88) and 97% (95% CI 95–98).
Discussion
The efficiency of two P. falciparum-specific RDTs, i.e.,
HRP2 and LDH were studied for assessment of clear-
ance and detection of recurrent infections during 42 days
after initiation of artemether-lumefantrine treatment.
This was done through a comparison with two micros-
copy techniques and real-time PCR. HRP2 had a
significantly longer median clearance time (28 days)
compared with LDH (seven days). Due to persistent
HRP2 positivity from the initial infection, only two out
of the ten children with recurrent P. falciparum infec-
tions during follow-up were identified by HRP2, whereas
LDH was able to recognize eight at the time of parasite
recurrence. Acridine orange blood smear microscopy did
not provide any additional information compared with
the other tests used in this study.
Clearance
Long clearance times for HRP2-based RDTs after ACT
treatment have previously been shown [6,26,27], with
remaining HRP2 positivity by day 35 in up to 73% of
Table 2 Characterization of the ten recurrent Plasmodium falciparum infections detected during follow-up
Diagnosis
day
Symptom Diagnostic tool Parasites New infection/
PCR Giemsa LDH-RDT /μL Recrudescence2
1 14 A + + 80 New
2 21 A + + + 1,600 New
3 21 R + + undertermined
4 21 1 + + 1 600 recrudescence
5 21 F + + undertermined
6 28 A + + + 316,000 new
7 28 F + + + 229,600 new
8 35 F + + + 61,240 undertermined
9 35 F + + + 9,800 new
10 35 F + + + 33,920 new
A = asymptomatic F = fever R = respiratory tract infection.
1turned positive with fever following visit.
2PCR corrected outcome.
Figure 5 Cumulative positivity by the diagnostic tests for the ten recurrent Plasmodium falciparum infections detected during follow-up.
BS = Giemsa-stained blood smear. AO = acridine orange-stained blood smear.
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patients despite efficacious treatment. Initial parasite
density has been suggested to influence the duration of
HRP2 positivity, but a patient’s immune status may also
be a contributing factor [28].
Similarly with the present findings, a relatively rapid
clearance of LDH has previously been documented
[10,12]. It has been claimed that especially HRP2 but
also LDH are released by immature gametocytes, which
may result in persistent positive test results [5,29]. How-
ever, this opinion has been challenged by others who
argue that the number of gametocytes after ACT treat-
ment are too few to cause persistent positivity [30]. Im-
portantly, in our this study, only four solely gametocyte
carriers were detected by Giemsa-stained blood smear
microscopy, of whom three and none were HRP2 and
LDH positive, respectively, during gametocyte carriage.
Expert blood smear microscopy remains gold standard
for estimation of parasite clearance in clinical trials of
anti-malarial drugs. Blood smear positivity by day 3, i.e.,
72 hours after initiation of ACT treatment, was observed
in 4/53 (8%) of the patients. This is a relatively uncom-
mon finding among African children treated with
ACT for uncomplicated malaria [27,31]. The prolonged
Giemsa-stained blood smear positivity may be explained
by poor compliance since only the initial artemether-
lumefantrine dose, i.e., one out of six doses, was given
under supervision. Similarly, the relatively long mean
PCR clearance time observed may possibly be explained
by poor compliance. The presence of gametocyte car-
riage in patients with prolonged PCR positivity during
follow-up may also have influenced the PCR clearance
time.
Parasite density day 0 and persistent HRP2
No correlation was observed between parasite density at
enrolment and duration of HRP2 positivity. This is in
contrast to several previous publications that report a
strong positive correlation [5,6,26,27]. However, these
studies have generally included a wider range of parasite
densities down to <1,000/μL, where clustering has shown a
shorter HRP2 clearance time in parasitaemias <10,000/μL.
Conversely, Choidini et al. identified a wide range of
HRP2 concentrations at equal parasite densities both
in panels of cultures and of field isolates [32]. Varying
HRP2 concentrations may be dependent on factors
such as the duration of infection, the total parasite
biomass including the sequestered parasites [33] and
anti-HRP2 immune response.
Detection of recurrent infections
In the moderately high transmission area where the
study was conducted, ten (19%) children had recurrent
infection detected between days 14 and 35 during
follow-up. All recurrent infections were detected by
PCR, whereas both the LDH-based RDT and Giemsa-
stained blood smear detected eight, HRP2 identified two
and acridine orange smear microscopy identified only
one of these infections at the time of parasite recurrence.
Few other studies have looked at the efficiency of RDTs
for detection of recurrent infections during follow-up
after anti-malarial treatment. Maxay et al. found in a
study performed in Thailand that 40/92 (43%) patients
experienced recurrent infection during a 28-day follow-
up [5]. All these patients had persistent HRP2 positivity
from enrolment up to day of recurrent infection.
RDTs for assessment of treatment outcome
The usefulness of RDTs for monitoring of anti-malarial
treatment, i.e., clearance time as well as identification of
treatment failure/re-infection, is highly dependent on
test specificity. HRP2-based RDTs appear not to be a
sufficient tool for this. LDH, with a limited but still lon-
ger clearance time as compared with blood smear mi-
croscopy, may be useful but for detection of prolonged
parasite clearance as a sign of emerging artemisinin
tolerance/resistance, it is probably not sufficient.
RDTs for case detection
Sensitivity and specificity of the HRP2 and LDH antigens
for case detection are highly dependent on malaria en-
demicity [27,28]. In high endemic areas HRP2 generally
shows a low specificity, especially among febrile chil-
dren, because a large proportion of residents have
remaining antigenaemia from previous infections. The
generally higher parasite densities observed in high en-
demic areas may also cause longer HRP2 clearance times
affecting the specificity. However, Abeku et al. showed
that in an area of high transmission the specificity in-
creased towards the end of the rainy seasons, and in
older age groups probably due to increased HRP2 anti-
body levels in the population. In low endemic areas the
specificity of HRP2 among febrile patients generally
Table 3 Specificities of the Plasmodium falciparum HRP2
and LDH-based rapid diagnostic tests against Giemsa-
stained blood slide microscopy (gold standard) between
days 3 and 42
HRP2 LDH
Day % CI 95% % CI 95% p-value
3 NA 20/49 41 27-56
7 NA 40/53 76 62-86
14 11/52 21 11-35 51/52 98 90-100 <0.0001
21 17/50 34 21-49 48/50 96 86-100 <0.0001
28 29/49 59 44-73 49/49 100 93-100 <0.0001
35 35/50 70 55-82 48/50 96 86-100 <0.005
42 45/52 87 74-94 50/52 96 87-100 >0.05
NA = not applicable.
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increases due to the low malaria incidence and thus the
low risk of detecting remaining antigenaemia after
cleared infections. LDH, on the other hand, which has
shown a comparatively lower sensitivity for detection of
P. falciparum infections with densities <200/μL, may in
areas of low transmission where parasite densities gener-
ally are lower especially among asymptomatic cases [34],
be a less efficient diagnostic tool than HRP2.
Other limitations with HRP2-based RDTs are the gen-
etic diversity, including the deletions recently described
among African P. falciparum isolates [35,36], as well as
false HRP2 negative results due to the prozone effect
[37]. To date, no genetic LDH diversity/deletion has
been described and LDH-based RDTs are not susceptible
to any prozone effect [38,39]. All these factors should be
considered for the choice of RDT in a specific epidemio-
logical setting.
What does the present study add to the knowledge base
of RDTs?
Previous RDT studies in this particular field have mainly
followed up the study participants until the RDTs have
become negative [12,13]. Conversely, all five diagnostic
tests were assessed up to day 42 after treatment initi-
ation in this report. This study design provides a more
comprehensive assessment both of clearance times and of
recurrent malaria infections for all diagnostic methods,
and importantly assesses the efficiency of the two RDTs
to detect recurrent malaria infections, which has previ-
ously not been reported. Eight of the ten recurrent in-
fections in this study were recognized by LDH at the
day of infection and another one on the following sam-
pling day, whereas HRP2 detected only two of the recur-
rent infections. These results, in combination with the
significantly shorter median clearance time of LDH
compared with HRP2, provide evidence for the former
to be a better tool for monitoring of anti-malarial treat-
ment outcome among children with symptomatic infec-
tion in this moderately high endemic area. In addition,
this study is the first to incorporate PCR as a compara-
tor for assessment of clearance.
Limitations
A general limitation when assessing performance of
parasite based diagnostic tests that indeed detect differ-
ent things such as antigens (RDT), DNA (PCR) or whole
parasites (microscopy) is that the results are not fully
comparable. Furthermore, this is a small study with a
limited number of patients with recurrent infections
detected during follow-up.
Conclusion
The LDH-based RDT was superior to HRP2-based for
monitoring of treatment outcome and detection of
recurrent infections after ACT in this moderately high
transmission setting. The results may have implications
for the choice of RDT devices in similar transmission
settings for improved malaria case management.
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